UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, ~~2021~~2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to_____

Commission File Number 001-36533

MEDAVAIL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

90-0772394

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification Number)

6665 Millcreek Dr. Unit 1, Mississauga ON Canada

L5N 5M4

(Address of principal executive offices)

(Zip Code)

+1 (905) 812-0023

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

MDVL

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐☒ No ☒☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May ~~14, 2021,~~11, 2022, there were ~~32,520,833~~70,555,977 shares of the registrant’s common stock outstanding.

MedAvail Holdings, Inc.

Form 10-Q

For the Three Months Ended March 31, ~~2021~~2022

TABLE OF CONTENTS


		Page

PART I
Item 1.	Financial Statements	45
	Consolidated Condensed Balance Sheets	4
	~~Consolidated Condensed Statements of Operations~~	5
	Consolidated Condensed Statements of Operations and Comprehensive Loss	65
	Consolidated Condensed Statements of ~~Shareholders~~Shareholders' Equity (Deficit)	76
	Consolidated Condensed Statements of Cash Flows	87
	Notes to Consolidated Condensed Financial Statements	9
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	1920
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	2627
Item 4.	Controls and Procedures	2627

PART II
Item 1.	Legal Proceedings	2728
Item 1A.	Risk Factors	2728
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3128
Item 3.	Defaults Upon Senior Securities	3128
Item 4.	Mine Safety Disclosures	3128
Item 5.	Other Information	3128
Item 6.	Exhibits	3229

Signatures		3430

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

These forward-looking statements include, but are not limited to, statements about:

•our plans to modify our current products, or develop new products;

•the expected growth of our business and organization;

•our expectations regarding the size of our sales organization and expansion of our sales and marketing efforts;

•our ability to retain and recruit key personnel, including the continued development of a sales and marketing infrastructure;

•our ability to obtain and maintain intellectual property protection for our products;

•our ability to expand our business into new geographic markets;

•our compliance with extensive Nasdaq requirements and government laws, rules and regulations both in the United States and internationally;

•our estimates of expenses, ongoing losses, future revenue, capital requirements and our need for, or ability to obtain, additional financing;

•our ability to identify and develop new and planned products and/or acquire new products;

•the expectations regarding the impact of the COVID-19 pandemic on our business;

•existing regulations and regulatory developments in the United States, Canada and other jurisdictions;

•the impact of laws and regulations;

•our financial performance;

•the period over which we estimate our existing cash, cash equivalents and available-for-sale investments will be sufficient to fund our future operating expenses and capital expenditure requirements;

•our anticipated use of our existing resources; and

•developments and projections relating to our competitors or our industry.

We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. These forward-looking statements are based on management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q. Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. We assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any

forward-looking statements for any reason after the date of this Quarterly Report on Form 10-Q to conform these statements to actual results or to changes in our expectations.

You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the SEC as exhibits to the Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

PART I

Item 1. Financial Statements

MEDAVAIL HOLDINGS, INC.

Consolidated Condensed Balance Sheets

(Unaudited)

(~~US Dollars~~ in thousands, except share amounts)


		March 31,		December 31,			March 31,		December 31,
		2021		2020			2022		2021

Assets	Assets					Assets
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	47,582	$	57,936	Cash and cash equivalents	$	5,274	$	19,689
Restricted cash	Restricted cash	61		60		Restricted cash	676		400
Accounts receivable (net of allowance for doubtful accounts of $0.03 million for March 31, 2021, $0.04 million for December 31, 2020)		1,404		1,520
Accounts receivable (net of allowance for doubtful accounts of $96 thousand for March 31, 2022, $66 thousand for December 31, 2021)						Accounts receivable (net of allowance for doubtful accounts of $96 thousand for March 31, 2022, $66 thousand for December 31, 2021)	1,748		1,189
Inventories	Inventories	3,119		2,817		Inventories	5,088		3,916
Prepaid expenses and other current assets	Prepaid expenses and other current assets	1,455		1,534		Prepaid expenses and other current assets	3,105		2,191
Total current assets	Total current assets	53,621		63,867		Total current assets	15,891		27,385
Property, plant and equipment, net	Property, plant and equipment, net	3,782		3,795		Property, plant and equipment, net	6,175		5,692
Intangible assets, net						Intangible assets, net	2,765		2,300
Right-of-use assets	Right-of-use assets	1,318		1,239		Right-of-use assets	2,628		2,538
Other assets	Other assets	203		203		Other assets	233		228
Intangible assets		614		227
Total assets	Total assets	$	59,538	$	69,331	Total assets	$	27,692	$	38,143
Liabilities and Stockholders' Equity	Liabilities and Stockholders' Equity					Liabilities and Stockholders' Equity
Current liabilities:	Current liabilities:					Current liabilities:
Accounts payable and accrued liabilities	Accounts payable and accrued liabilities	$	3,802	$	4,512	Accounts payable and accrued liabilities	$	8,527	$	6,740
Short-term debt		2,000		2,161
Contract liability		262		275

Deferred revenue						Deferred revenue	107		83
Current portion of lease obligations	Current portion of lease obligations	605		665		Current portion of lease obligations	733		682
Total current liabilities	Total current liabilities	6,669		7,613		Total current liabilities	9,367		7,505

Long-term debt, net						Long-term debt, net	9,608		9,538
Long-term portion of lease obligations	Long-term portion of lease obligations	788		651		Long-term portion of lease obligations	2,102		2,027

Total liabilities	Total liabilities	7,457		8,264		Total liabilities	21,077		19,070

Commitments and contingencies						Commitments and contingencies	0		0
Stockholders' deficit:	Stockholders' deficit:					Stockholders' deficit:
Common shares ($0.001 par value, 100,000,000 shares authorized, 31,939,898 and 31,816,020 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively)		32		32
Common shares ($0.001 par value, 100,000,000 shares authorized, 32,908,922 and 32,902,048 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively)						Common shares ($0.001 par value, 100,000,000 shares authorized, 32,908,922 and 32,902,048 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively)	33		33
Warrants	Warrants	2,579		2,614		Warrants	1,373		1,373
Additional paid-in-capital	Additional paid-in-capital	214,125		213,624		Additional paid-in-capital	217,249		216,685
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(6,928)		(6,928)		Accumulated other comprehensive loss	(6,928)		(6,928)
Accumulated deficit	Accumulated deficit	(157,727)		(148,275)		Accumulated deficit	(205,112)		(192,090)
Total stockholders' equity	Total stockholders' equity	52,081		61,067		Total stockholders' equity	6,615		19,073
Total liabilities and stockholders' equity	Total liabilities and stockholders' equity	$	59,538	$	69,331	Total liabilities and stockholders' equity	$	27,692	$	38,143

The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.

Going concern (Note 2).

MEDAVAIL HOLDINGS, INC.

Consolidated Condensed Statements of Operations and Comprehensive Loss

(Unaudited)

(~~US Dollars~~ in thousands, except share and per-share amounts)


		Three Months Ended March 31,					Three Months Ended March 31,
		2021		2020				2022		2021
Sales:
Pharmacy and hardware sales		$	3,781	$	1,402
Service sales		246		10
Total sales		4,027		1,412
Cost of sales:
Pharmacy and hardware cost of sales		3,526		1,385
Service cost of sales		181		47
Total cost of sales		3,707		1,432
Gross profit (loss)		320		(20)
Revenue:						Revenue:
Pharmacy and hardware revenue						Pharmacy and hardware revenue		$	9,014	$	3,781
Service revenue						Service revenue		100		246
Total revenue						Total revenue		9,114		4,027
Cost of products sold and services:						Cost of products sold and services:
Pharmacy and hardware cost of products sold						Pharmacy and hardware cost of products sold		8,563		3,526
Service costs						Service costs		50		181
Total cost of products sold and services						Total cost of products sold and services		8,613		3,707
Operating expense:						Operating expense:

Pharmacy operations	Pharmacy operations	1,911		1,089		Pharmacy operations		3,929		2,593
General and administrative	General and administrative	6,515		3,500		General and administrative		6,535		5,676
Selling and marketing	Selling and marketing	1,377		703		Selling and marketing		2,313		1,534
Research and development	Research and development	168		215		Research and development		493		168

Total operating expense						Total operating expense		13,270		9,971
Operating loss	Operating loss	(9,651)		(5,527)		Operating loss		(12,769)		(9,651)
Other gain (loss), net	Other gain (loss), net	161		8		Other gain (loss), net		—		161
Interest income	Interest income	40		8		Interest income		1		40
Interest expense	Interest expense	(2)		(179)		Interest expense		(254)		(2)
Loss before income taxes	Loss before income taxes	(9,452)		(5,690)		Loss before income taxes		(13,022)		(9,452)
Income tax		0		0
Net loss		$	(9,452)	$	(5,690)
Income tax expense						Income tax expense		—		—
Net loss and comprehensive loss						Net loss and comprehensive loss		$	(13,022)	$	(9,452)
Net loss per share - basic and diluted	Net loss per share - basic and diluted	$	(0.29)	$	(3.15)	Net loss per share - basic and diluted		$	(0.40)	$	(0.27)
Weighted average shares outstanding - basic and diluted	Weighted average shares outstanding - basic and diluted	32,439,953		1,808,105		Weighted average shares outstanding - basic and diluted		32,921,969		34,439,953

The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.

MEDAVAIL HOLDINGS, INC.

Consolidated Condensed ~~Statement of Comprehensive Loss~~

~~(Unaudited)~~

~~(US Dollars in thousands, except per-share amounts)~~

Three Months Ended March 31,
2021 2020
Net loss $ (9,452) $ (5,690)
Other comprehensive loss:
Foreign currency translation adjustment 0 (2)
Total comprehensive loss $ (9,452) $ (5,692)

~~The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.~~

~~MEDAVAIL HOLDINGS, INC.~~

~~Consolidated Condensed~~ Statements of Shareholders' Equity ~~(Deficit)~~

(Unaudited)

(~~US Dollars~~ in thousands, except per share amounts)

Three Months Ended March 31, 2021
Common Shares Preferred Shares * Warrants Additional Paid-in-Capital Accumulated Deficit Accumulated Other Comprehensive Loss Total Stockholders' Equity (Deficit)
Shares Amount Shares Amount
Balance at December 31, 2020 31,816,020 $ 32 — $ — $ 2,614 $ 213,624 $ (148,275) $ (6,928) $ 61,067
Net loss — — — — — — (9,452) — (9,452)
Shares issued for options exercises 120,924 — — — — 201 — — 201
Exercise of warrants 2,954 — — — (35) 40 — — 5
Share-based compensation — — — — — 260 — — 260
Balance at March 31, 2021 31,939,898 $ 32 — $ — $ 2,579 $ 214,125 $ (157,727) $ (6,928) $ 52,081
Three Months Ended March 31, 2020
Common Shares Preferred Shares * Warrants Additional Paid-in-Capital Accumulated Deficit Accumulated Other Comprehensive Loss Total Stockholders' Deficit
Shares Amount Shares Amount
Balance at December 31, 2019 1,504,251 $ 8 10,500,440 $ 93,484 $ 698 $ 30,829 $ (121,230) $ (6,950) $ (3,161)
Net loss — — — — — — (5,690) — (5,690)
Issuance of preferred shares — — 102,777 788 — — — — 788
Shares issued for options exercises 17,160 — — — — 27 — — 27
Share-based compensation — — — — — 84 — — 84
Warrants issued — — — — 435 (11) — — 424
Cumulative translation adjustment — — — — — — — (2) (2)
Balance at March 31, 2020 1,521,411 $ 8 10,603,217 $ 94,272 $ 1,133 $ 30,929 $ (126,920) $ (6,952) $ (7,530)

* $0.001 par value, 10,000,000 shares authorized at March 31, 2021 and December 31 2020. $0.001 par value, 14,539,330 shares authorized at March 31, 2020.


	Common Shares			Warrants			Additional Paid-in-Capital			Accumulated Deficit			Accumulated Other Comprehensive Loss			Total Stockholders' Equity
	Shares	Amount







Balance at December 31, 2021	32,902,048	$	33		$	1,373		$	216,685		$	(192,090)		$	(6,928)		$	19,073
Net loss	—	—			—			—			(13,022)			—			(13,022)
Shares issued for vested RSUs	6,874	—			—			—			—			—			—


Share-based compensation	—	—			—			564			—			—			564
Balance at March 31, 2022	32,908,922	$	33		$	1,373		$	217,249		$	(205,112)		$	(6,928)		$	6,615
















Balance at December 31, 2020	31,816,020	32			2,614			213,624			(148,275)			(6,928)			61,067
Net loss	—	—			—			—			(9,452)			—			(9,452)
Shares issued for options exercises	120,924	—			—			201			—			—			201
Exercise of warrants	2,954	—			(35)			40			—			—			5
Share-based compensation	—	—			—			260			—			—			260


Balance at March 31, 2021	31,939,898	$	32		$	2,579		$	214,125		$	(157,727)		$	(6,928)		$	52,081

The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.

MEDAVAIL HOLDINGS, INC.

Consolidated Condensed Statement of Cash Flows

(Unaudited)

(~~US Dollars~~ in thousands)


		Three Months Ended March 31,					Three Months Ended March 31,
		2021		2020			2022		2021
Cash flows from operating activities:	Cash flows from operating activities:					Cash flows from operating activities:
Net loss	Net loss	$	(9,452)	$	(5,690)	Net loss	$	(13,022)	$	(9,452)
Adjustments to reconcile net loss to net cash used in operating activities:	Adjustments to reconcile net loss to net cash used in operating activities:					Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant, and equipment	Depreciation of property, plant, and equipment	295		204		Depreciation of property, plant, and equipment	286		295
Amortization of intangible and leased assets	Amortization of intangible and leased assets	207		188		Amortization of intangible and leased assets	312		207
Bad debt and other non cash receivables adjustments						Bad debt and other non cash receivables adjustments	30		15
Term loan discount amortization and interest accretion on debt						Term loan discount amortization and interest accretion on debt	70		2

Bad debt and other non cash receivables adjustments		15		0
Interest accretion on debt and finance leases		2		179
Unrealized foreign currency (loss) gain		0		(2)
Stock compensation expense		260		84
Share-based compensation expense						Share-based compensation expense	564		260

PPP loan forgiveness gain	PPP loan forgiveness gain	(161)		0		PPP loan forgiveness gain	—		(161)
Warrant expense		0		22

Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Change in accounts receivable	Change in accounts receivable	101		(118)		Change in accounts receivable	(589)		101
Change in inventory	Change in inventory	(360)		(242)		Change in inventory	(1,601)		(360)
Change in prepaid expenses and other current assets	Change in prepaid expenses and other current assets	79		(50)		Change in prepaid expenses and other current assets	(914)		79
Change in accounts payable, accrued expenses and other liabilities	Change in accounts payable, accrued expenses and other liabilities	(639)		(331)		Change in accounts payable, accrued expenses and other liabilities	1,705		(639)
Change in contract liability		(13)		(6)
Change in deferred revenue						Change in deferred revenue	24		(13)
Change in operating lease liability due to cash payments	Change in operating lease liability due to cash payments	(164)		(137)		Change in operating lease liability due to cash payments	(129)		(164)
Net cash used in operating activities	Net cash used in operating activities	(9,830)		(5,899)		Net cash used in operating activities	(13,264)		(9,830)
Cash flows from investing activities:	Cash flows from investing activities:					Cash flows from investing activities:
Purchase of property, plant and equipment	Purchase of property, plant and equipment	(260)		(154)		Purchase of property, plant and equipment	(343)		(260)
Payment of security deposits	Payment of security deposits	0		(44)		Payment of security deposits	(5)		—
Purchase of intangible assets and other assets	Purchase of intangible assets and other assets	(452)		(5)		Purchase of intangible assets and other assets	(504)		(452)
Net cash used in investing activities	Net cash used in investing activities	(712)		(203)		Net cash used in investing activities	(852)		(712)
Cash flows from financing activities:	Cash flows from financing activities:					Cash flows from financing activities:

Issuance of common shares upon exercise of options and warrants	Issuance of common shares upon exercise of options and warrants	206		27		Issuance of common shares upon exercise of options and warrants	—		206

Issuance of preferred shares		0		788

Payments on finance lease obligations	Payments on finance lease obligations	(17)		0		Payments on finance lease obligations	(23)		(17)

Net cash provided by financing activities		189		815
Net cash (used in) provided by financing activities						Net cash (used in) provided by financing activities	(23)		189
Net decrease in cash, cash equivalents and restricted cash	Net decrease in cash, cash equivalents and restricted cash	(10,353)		(5,287)		Net decrease in cash, cash equivalents and restricted cash	(14,139)		(10,353)
Cash, cash equivalents and restricted cash at beginning of period	Cash, cash equivalents and restricted cash at beginning of period	57,996		8,849		Cash, cash equivalents and restricted cash at beginning of period	20,089		57,996
Cash, cash equivalents and restricted cash at end of period	Cash, cash equivalents and restricted cash at end of period	$	47,643	$	3,562	Cash, cash equivalents and restricted cash at end of period	$	5,950	$	47,643

Supplemental noncash investing and financing activities:
Inventory transferred to property, plant and equipment		$	58	$	591
Property, plant and equipment transferred to intangible assets		$	36	$	0

Conversion of other liability amount into warrants		$	0	$	402
Lease liabilities arising from obtaining right of use assets:
Operating leases		$	279	$	425
Finance leases		$	0	$	23

The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.

MEDAVAIL HOLDINGS, INC.

Consolidated Condensed Statement of Cash Flows

(Unaudited)

(in thousands)


	Three Months Ended March 31,
	2022		2021
Supplemental noncash investing and financing activities:
Inventory transferred to property, plant and equipment	$	429	$	58
Property, plant and equipment transferred to intangible assets	$	—	$	36
Purchase of property, plant and equipment in accounts payable	$	122	$	—
Purchase of intangible assets in accounts payable	$	326	$	—

Lease liabilities arising from obtaining right of use assets:
Operating leases	$	205	$	279
Finance leases	$	73	$	—

The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.

MEDAVAIL HOLDINGS, INC.

Notes to Consolidated Condensed Financial Statements

(Unaudited)

NOTE 1 - NATURE OF OPERATIONS

MedAvail Holdings, Inc., or MedAvail, or the Company, a Delaware corporation formerly known as MYOS RENS Technology, is a ~~telehealth-enabled~~ pharmacy technology and services company that has developed and commercialized an innovative self-service pharmacy, mobile application, kiosk and drive-thru solution. ~~MedAvail's~~The Company’s principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter facilitates live pharmacist ~~counselling~~counseling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control. ~~MedAvail~~The Company also operates SpotRx, or the Pharmacy, a full-service retail pharmacy utilizing the Company’s automated pharmacy technology.

NOTE 2 - GOING CONCERN

Relevant accounting standards require that management make a determination as to whether or not substantial doubt exists as to our ability to continue as a going concern. If substantial doubt does exist, then management should determine if there are plans in place which alleviate that doubt. Since inception through March 31, 2022, the Company continually incurred losses from operations which have been financed primarily by net cash proceeds from the sale of stock from private placements, the sale of redeemable preferred stock and debt. Net cash used in operating activities for three months ended March 31, 2022 and 2021 was $13.3 million and $9.8 million, respectively. As of March 31, 2022, the Company had $5.3 million in cash and cash equivalents and an accumulated deficit of $205.1 million.

In April 2022, the Company completed a private placement, pursuant to which the Company received $40.0 million in gross proceeds, with an additional $10.0 million in anticipated gross proceeds to be received upon the second close expected to occur on July 1, 2022, subject to the satisfaction or waiver of the conditions to closing, before deducting placement agent commissions and other offering expenses. Additionally, the private placement included warrants, some of which may be callable at the Company’s option beginning on each of the 12 month and 24 month anniversaries of the warrant issuance dates and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. See Note 13 for further information regarding the private placement warrants.

Due to the Company’s significant and ongoing cash requirements to fund operations, management determined that there is substantial doubt as to the Company’s ability to continue as a going concern. The Company added liquidity resources in 2021 through a senior secured term loan facility with Silicon Valley Bank as described in Note 8, pursuant to which the Company borrowed $10.0 million in aggregate initial term loans. Additionally, as referenced above, the Company raised $40.0 million in gross proceeds through a private placement. There can be no assurance that the steps management is taking will be successful. If the Company is unable to raise additional capital in sufficient amounts or on acceptable terms, the Company may have to significantly reduce operations or delay, scale back or discontinue development and expansion plans. The consolidated condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on continued development and deployment of MedCenter kiosks and SpotRx pharmacy operations and the ability to raise significant additional funding.

NOTE 23 - BASIS OF PRESENTATION

The accompanying unaudited consolidated condensed financial statements as of March 31, ~~2021~~2022 and for the three months ended March 31, ~~2021~~2022 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information. Accordingly, the unaudited interim consolidated condensed financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The consolidated condensed balance sheet as of December 31, ~~2020~~2021 was derived from the Company's audited consolidated ~~condensed~~ financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which ~~includes~~include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, ~~2020~~2021 included in the Company's Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, which was filed with the Securities and Exchange Commission, or SEC on March ~~31, 2021,~~29, 2022, or the ~~2020~~2021 Form 10-K.

The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and ~~in-process~~in-

process research and development intangible assets, and impairment of long-lived assets and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated condensed financial statements in the period they are deemed to be necessary.

Risks and uncertainties relating to COVID-19

The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors, including but not limited to, the severity and duration of COVID-19, the extent to which it will impact our clinic customers, employees, suppliers, vendors, and business partners. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of March 31, ~~2021~~2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s recoverability of, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated condensed financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results could differ from these estimates and any such differences may ~~differ.~~be material to the Company’s financial statements.

Principles of consolidation

The unaudited consolidated condensed financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include, MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.

Reclassifications

During the fourth quarter of 2021, management reclassified certain operating expenses to reflect the costs attributable to pharmacy operations. Specifically, certain costs were reclassified from general and administrative expenses, to pharmacy operations expenses and selling and marketing expenses. This reclassification had no impact on the operating loss subtotal within the consolidated statements of operations and comprehensive loss. The effect of the reclassifications within the consolidated condensed statement of operations and comprehensive loss for 2021 is as follows (in thousands):


	Three Months Ended March 31, 2021
	Current presentation		As previously reported		Change
Pharmacy operations	$	2,593	$	1,911	$	682
General and administrative	5,676		6,515		(839)
Selling and marketing	1,534		1,377		157
	$	9,803	$	9,803	$	—

NOTE 34 - RECENT ACCOUNTING PRONOUNCEMENTS

Measurement of Credit Losses on Financial Statements

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. This ASU will be effective beginning in the first quarter of our fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated condensed financial statements and related disclosures.

Recently Adopted Accounting Standards

~~Simplifying the Accounting for Income Taxes~~

In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”). This guidance removes certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. This guidance also clarifies and simplifies other areas of ASC 740. This ASU will be effective beginning in the first quarter of our fiscal year 2021. Early adoption is permitted. Certain amendments in this update must be applied on a prospective basis, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings/(deficit) in the period of adoption. MedAvail assessed the impact of the new accounting standard on its consolidated condensed financial statements to facilitate its required adoption of the new standard on January 1, 2021. The adoption of ASU 2019-12 did not result in a material change to our consolidated condensed financial statements.

~~Debt with Conversion and Other Options~~

In August 2020, the FASB issued ASU No. 2020-06, “Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting For Convertible Instruments and Contracts in an Entity's Own Equity” (“ASU 2020-06”). The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The ASU also simplifies the diluted net income per share calculation in certain areas. MedAvail assessed the impact of the new accounting standard on its consolidated condensed financial statements to facilitate its early adoption of the new standard on January 1, 2021. The adoption of ASU 2020-06 did not result in a material change to our consolidated condensed financial statements.

There were no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated condensed financial statements through the reporting date.

NOTE 45 - EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period.

The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise ~~price:~~price, during the period they were outstanding up to when they were exercised. After these warrants were exercised the related issued and outstanding common shares are included in weighted average shares outstanding:

Issuance Date

Exercise Date

118,228

May 9, 2018

May 10, 2021

309,698

February 11, 2020

May 10, 2021

84,911

June 29, 2020

May 10, 2021

~~58,518~~39,208

November 18, 2020

May 10, 2021

19,310

November 18, 2020

Outstanding

During the three months ended March 31, ~~2021~~2022 and ~~2020,~~2021, there was no ~~potential dilution~~dilutive effect from stock options or other warrants due to the Company’s net loss position. Weighted average shares for historical periods have been adjusted for the effect of the 1.26 for 1 split on November 17, 2020. The following table sets forth the computation of basic and diluted earnings per share.


		Three Months Ended March 31,				Three Months Ended March 31,
		2021		2020
(in thousands)							(in thousands)	2022		2021
Net loss - basic and diluted	Net loss - basic and diluted	$	(9,452)	$	(5,690)		Net loss - basic and diluted	$	(13,022)	$	(9,452)
Weighted average shares - basic and diluted	Weighted average shares - basic and diluted	32,439,953		1,808,105			Weighted average shares - basic and diluted	32,921,969		34,439,953
Net loss per share - basic and diluted	Net loss per share - basic and diluted	$	(0.29)	$	(3.15)		Net loss per share - basic and diluted	$	(0.40)	$	(0.27)

As of March 31, ~~2021~~2022 and ~~2020,~~2021, there were ~~2.5~~4.4 million and ~~2.4~~2.5 million, respectively, of option awards outstanding that were not included in the diluted shares calculation because their inclusion would have been antidilutive.

NOTE 56 - FAIR VALUE MEASUREMENTS

Assets and liabilities measured at fair value on a recurring basis were as follows:


				Fair Value Hierarchy									Fair Value Hierarchy
		March 31, 2021		Level 1		Level 2		Level 3
(in thousands)										(in thousands)	March 31, 2022		Level 1		Level 2		Level 3
Assets:	Assets:									Assets:
Cash and cash equivalents	Cash and cash equivalents	$	47,582	$	47,582	$	0	$	0	Cash and cash equivalents	$	5,274	$	5,274	$	—	$	—
Restricted cash	Restricted cash	61		61		0		0		Restricted cash	676		676		—		—
Total assets	Total assets	$	47,643	$	47,643	$	0	$	0	Total assets	$	5,950	$	5,950	$	—	$	—


				Fair Value Hierarchy									Fair Value Hierarchy
		December 31, 2020		Level 1		Level 2		Level 3
(in thousands)										(in thousands)	December 31, 2021		Level 1		Level 2		Level 3
Assets:	Assets:									Assets:
Cash and cash equivalents	Cash and cash equivalents	$	57,936	$	57,936	$	0	$	0	Cash and cash equivalents	$	19,689	$	19,689	$	—	$	—
Restricted cash	Restricted cash	60		60		0		0		Restricted cash	400		400		—		—
Total assets	Total assets	$	57,996	$	57,996	$	0	$	0	Total assets	$	20,089	$	20,089	$	—	$	—

The carrying amount of the Company's term loan approximates fair value based upon market interest rates available to us for debt of similar risk and maturities, a Level 2 input. Refer to Note 8, Debt, for further information.

NOTE 67 - BALANCE SHEET AND OTHER INFORMATION

~~Inventories~~Restricted cash

The Company considers cash to be restricted when withdrawal or general use is legally restricted. During the year ended December 31, 2021, the Company recovered the prior $0.06 million restricted cash balance that was held as a guarantee for certain purchasing cards. During the same period, pursuant to a Loan and Security Agreement with Silicon Valley Bank (see Note 8), the Company issued letters of credit to secure certain operating leases, and the Company is required to maintain a $0.68 million balance with the bank to secure the outstanding letters of credit. Due to the nature of the deposit, the balance is classified as restricted cash. Restricted cash is included in the balance for cash presented in the statements of cash flows.

Inventory

The following table presents detail of inventory balances:

March 31, December 31,
2021 2020
Inventories:
MedCenter hardware $ 1,576 $ 1,655
Pharmacy 1,150 837
Spare parts 393 325
Total inventories $ 3,119 $ 2,817


	March 31,		December 31,
(in thousands)	2022		2021
Inventory:
MedCenter hardware	$	1,589	$	1,201
Pharmaceuticals	2,904		2,150
Spare parts	595		565
Total inventory	$	5,088	$	3,916

~~During the three months ended March 31, 2021 and 2020, $3.4 million and $1.3 million, respectively, of pharmacy~~Pharmaceutical inventory was recognized in pharmacy and hardware cost of ~~sales. During~~products sold at $7.9 million and $3.1 million during the three months ended March 31, 2022 and 2021, ~~and 2020, $0.2 million and 0, respectively, of~~respectively. MedCenter ~~inventory~~hardware was recognized in pharmacy and hardware cost of ~~sales.~~

products sold at $0.1 million and $0.2 million during the three months ended March 31, 2022 and 2021, respectively.

Property, plant and equipment

The following tables present property, plant and equipment balances:


		Estimated useful lives		March 31,			December 31,			Estimated useful lives			March 31,			December 31,
			2021			2020
(in thousands)									(in thousands)			Estimated useful lives			2022			2021
Property, plant and equipment:	Property, plant and equipment:										Property, plant and equipment:
MedCenter equipment	MedCenter equipment	5 years		$	4,690		$	4,622	MedCenter equipment	8 years			$	6,861		$	5,875
IT equipment	IT equipment	1 - 3 years		2,071			1,999		IT equipment	1 - 3 years			2,373			2,361
Leasehold improvements	Leasehold improvements	lesser of useful life or term of lease		810			799		Leasehold improvements	lesser of useful life or term of lease			903			880
General plant and equipment	General plant and equipment	5 - 8 years		354			353		General plant and equipment	5 - 8 years			603			603
Office furniture and equipment	Office furniture and equipment	5 - 8 years		329			329		Office furniture and equipment	5 - 8 years			464			394
Vehicles	Vehicles	5 years		54			54		Vehicles	5 years			54			54
Construction-in-process	Construction-in-process			219			90		Construction-in-process				680			1,021
Total historical cost	Total historical cost			8,527			8,246		Total historical cost				11,938			11,188
Accumulated depreciation	Accumulated depreciation			(4,745)			(4,451)		Accumulated depreciation				(5,763)			(5,496)
Total property, plant and equipment, net	Total property, plant and equipment, net			$	3,782		$	3,795	Total property, plant and equipment, net				$	6,175		$	5,692

Depreciation expense of property and equipment was $0.3 million and ~~$0.2~~$0.3 million for the three months ended March 31, ~~2021~~2022 and ~~2020,~~2021, respectively. Depreciation expense included in pharmacy and hardware cost of ~~sales~~products sold was $0.03 million and $0.05 million for the three months ended March 31, 2022 and 2021, ~~and 2020,~~ respectively.

Intangible assets

The following table presents intangible asset balances:
March 31, December 31,
2021 2020
Gross intangible assets:
Intellectual property $ 3,857 $ 3,857
Software 2,235 1,815
Website and mobile application 583 583
Total intangible assets 6,675 6,255
Accumulated amortization:
Intellectual property (3,857) (3,857)
Software (1,621) (1,588)
Website and mobile application (583) (583)
Total accumulated amortization (6,061) (6,028)
Total intangible assets, net $ 614 $ 227


	March 31,		December 31,
(in thousands)	2022		2021
Gross intangible assets:
Intellectual property	$	3,857	$	3,857
Software	5,064		4,475
Website and mobile application	583		583
Total intangible assets	9,504		8,915
Accumulated amortization:
Intellectual property	(3,857)		(3,857)
Software	(2,299)		(2,175)
Website and mobile application	(583)		(583)
Total accumulated amortization	(6,739)		(6,615)
Total intangible assets, net	$	2,765	$	2,300

Amortization expense of intangible assets was ~~$0.03~~$0.12 million and ~~$0.04~~$0.03 million for the three months ended March 31, ~~2021~~2022 and ~~2020,~~2021, respectively, and are included in operating expenses.

Lessee leases

Balance sheet amounts for lease assets and leases liabilities are as follows:


		March 31,		December 31,			March 31,		December 31,
		2021		2020
(in thousands)						(in thousands)	2022		2021
Assets:	Assets:					Assets:
Operating	Operating	$	1,202	$	1,108	Operating	$	2,416	$	2,376
Finance	Finance	116		131		Finance	212		162
Total assets	Total assets	$	1,318	$	1,239	Total assets	$	2,628	$	2,538
Liabilities:	Liabilities:					Liabilities:
Operating:	Operating:					Operating:
Current	Current	$	554	$	612	Current	$	626	$	599
Long-term	Long-term	722		572		Long-term	1,996		1,947
Finance:	Finance:					Finance:
Current	Current	51		53		Current	107		83
Long-term	Long-term	66		79		Long-term	106		80
Total liabilities	Total liabilities	$	1,393	$	1,316	Total liabilities	$	2,835	$	2,709

The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows:
March 31, December 31,
2021 2020
Finance leases:
Weighted-average remaining lease term (years) 2.2 2.4
Weighted-average discount rate 6.0 % 6.0 %
Operating leases:
Weighted-average remaining lease term (years) 3.0 2.5
Weighted-average discount rate 6.0 % 6.0 %

~~Maturities of operating leases liabilities are as follows:~~

Remaining period in 2021 $ 505
2022 373
2023 226
2024 167
2025 98
2026 36
Thereafter 0
Total lease payments 1,405
Less: present value discount (129)
Total leases $ 1,276


	March 31,		December 31,
(in thousands)	2022		2021
Finance leases:
Weighted-average remaining lease term (years)	2.2		1.5
Weighted-average discount rate	8.4	%	8.8	%
Operating leases:
Weighted-average remaining lease term (years)	4.1		4.2
Weighted-average discount rate	6.9	%	6.9	%

Maturities of operating leases liabilities are as follows, in thousands:



Remaining period in 2022	$	602
2023	757
2024	617
2025	534
2026	468
2027	64
Thereafter	—
Total lease payments	3,042
Less: present value discount	(420)
Total leases	$	2,622

Maturities of finance lease liabilities are as ~~follows:~~follows, in thousands:


Remaining period in 2021		$	41
2022		57
Remaining period in 2022				Remaining period in 2022	$	92
2023	2023	27		2023	91
2024	2024	0		2024	47
2025	2025	0		2025	5
2026	2026	0		2026	—
2027				2027	—
Thereafter	Thereafter	0		Thereafter	—
Total finance lease payments	Total finance lease payments	125		Total finance lease payments	235
Less: imputed interest	Less: imputed interest	(8)		Less: imputed interest	(22)
Total leases	Total leases	$	117	Total leases	$	213

Operating lease expense was ~~$0.23~~$0.2 million and ~~$0.20~~$0.2 million for the three months ended March 31, ~~2021~~2022 and ~~2020,~~2021, respectively.

NOTE 78 - DEBT

The following table presents debt balances at March 31, ~~2021~~2022 and December 31, ~~2020:~~2021:

March 31, December 31,
2021 2020
Short-term note due May 2021 $ 1,000 $ 1,000
Short-term note due November 2021 1,000 1,000
PPP loan 0 161
Total debt 2,000 2,161
Less short term debt (2,000) (2,161)
Long-term debt $ 0 $ 0


	March 31,		December 31,
(in thousands)	2022		2021
Term loan	10,100		10,070
Term loan issuance costs, net	(492)		(532)
Total debt, net	9,608		9,538
Less short term debt	—		—
Long-term debt, net	$	9,608	$	9,538

~~Short-term notes~~Term loan

The ~~notes do~~Term loan bears interest at a floating rate equal to the greater of 7.25% or the Prime Rate plus 4.0% (7.25% at March 31, 2022). The Company could borrow up to an additional $20.0 million in aggregate term loans on or before April 30, 2022, however this option was not ~~accrue interest~~used and ~~may be repaid early without penalty. On May 14, 2021 we repaid $1.0 million on the Short-term note in accordance with the maturity schedule.~~

~~PPP loan~~

~~MedAvail received forgiveness approval of the loan on March 30, 2021 in accordance with the terms of the CARES Act.~~expired.

NOTE 89 - INCOME TAXES

The Company ~~did not incur~~incurred minimal income tax expense for the three months ended March 31, ~~2021, and 2020, respectively,~~2022, due to ongoing ~~losses.~~losses and minimum state income tax obligations. The effective income tax rate in each period differed from the federal statutory tax rate of 21% primarily as a result of the ongoing losses.

As of March 31, ~~2021,~~2022, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future.

On March 11, 2021, the U.S. federal government enacted the American Rescue Plan Act of 2021, which did not have a material impact on our benefit for income taxes.

NOTE 910 - COMMITMENTS AND CONTINGENCIES

Legal

Following MYOS Rens Technology Inc.’s, or MYOS’s and MedAvail, Inc.’s, or MAI's, announcement of the execution of the Merger Agreement on June 30, 2020, MYOS received separate litigation demands from purported MYOS stockholders on September 16, 2020 and October 20, 2020, respectively seeking certain additional disclosures in the Form S-4 Registration Statement filed with the Securities and Exchange Commission on September 2, 2020, collectively, the Demands. Thereafter, on September 23, 2020, a complaint regarding the transactions contemplated within the Merger Agreement was filed in the Supreme Court of the State of New York, County of New York, captioned Faasse v. MYOS RENS Technology Inc., et. al., Index No.: 654644/2020 (NY Supreme Ct., NY Cnty., September 23, 2020), or the New York Complaint. On October 12, 2020, a second complaint regarding the transactions was filed in the District Court of Nevada, Clark County Nevada, captioned Vigil v. Mannello, et. al., Case No. A-20-822848-C, or the Nevada Complaint, and together with the New York Complaint, the Complaints, and collectively with the Demands, the Litigation.

The Demands and the Complaints that comprise the Litigation generally alleged that the directors of MYOS breached their fiduciary duties by entering into the Merger Agreement, and MYOS and MAI disseminated an incomplete and misleading Form S-4 Registration Statement. The New York Complaint also alleged MedAvail aided and abetted such breach of fiduciary duties.

MYOS and MAI believe that the claims asserted in the Litigation are without merit, and believe that the Form S-4 Registration Statement disclosed all material information concerning the Merger and no supplemental disclosure is required under applicable law. However, in order to avoid the risk of the Litigation delaying or adversely affecting the Merger and to minimize the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, MYOS determined to voluntarily supplement the Form S-4 Registration Statement as described in the Current Report on Form 8-K on November 2, 2020. Subsequently, the Nevada Complaint and the New York Complaint were voluntarily dismissed. The remainder of the Litigation remains outstanding. MYOS and MAI specifically deny all allegations in the Litigation and/or that any additional disclosure was or is ~~required~~required.

NOTE 1011 - SHARE-BASED COMPENSATION AND WARRANTS

Share-based compensation

The following table presents the Company's expense related to share-based ~~compensation:~~compensation, in thousands:

Three Months Ended March 31,
2021 2020
Share-based compensation $ 260 $ 84


	Three Months Ended March 31,
	2022		2021
Share-based compensation	$	564	$	260

The share-based compensation expense for the three months ended March 31, 2022, included $0.03 million from 2020 ESPP expense. Expense remaining to be recognized for unvested option awards from the 2012, 2018, and 2020 plans as of March 31, ~~2021~~2022 was ~~$2.3~~$2.7 million, which will be recognized on a weighted average basis over the next ~~3.0~~3.2 years. Expense remaining to be recognized for unvested RSU awards was $2.7 million will be recognized on a weighted average basis over the next 2.7 years.

The following table ~~present~~presents the Company's outstanding option awards activity during the three months ended March 31, ~~2021:~~2022:

Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value
Outstanding, beginning of period 2,439,020 $ 1.59 USD $ 0.77 USD $ 31,174,927 USD
Granted 200,047 $ 14.75 USD $ 8.04 USD $ 0 USD
Exercised/Released (120,905) $ 1.69 USD $ 15.05 USD $ 0.85 USD $ 1,619,138 USD
Cancelled/Forfeited (1,909) $ 1.66 USD $ 0.84 USD $ 23,917 USD
Outstanding, end of period 2,516,253 $ 2.63 USD $ 1.34 USD 8.1 $ 28,802,808 USD
Vested and exercisable, end of the period 1,695,084 $ 1.64 USD $ 0.79 USD 7.7 $ 20,956,155 USD
Vested and unvested exercisable, end of the period 1,695,084 $ 1.64 USD $ 0.79 USD 7.7 $ 20,956,155 USD
Vested and expected to vest, end of the period 2,453,394 $ 2.55 USD $ 1.30 USD 8.1 $ 28,255,632 USD


(in thousands, except for share and per share amounts)	Number of Awards	Weighted Average Exercise Price		Weighted Average Share Price on Date of Exercise	Weighted Average Fair Value		Weighted Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding, beginning of period	2,848,903	$	2.78		$	1.44	0	$	31
Granted	1,749,015	1.18			0.85			—
Exercised/Released	—	—			—			—
Expired	(117,730)	2.11			1.15			—
Forfeited	(127,617)	3.18			1.66			—
Outstanding, end of period	4,352,571	$	2.15		$	1.21	8.54	$	40
Vested and exercisable, end of the period	1,710,753	2.17			1.07		6.88	—
Vested and unvested exercisable, end of the period	1,710,753	2.17			1.07		6.88	—
Vested and expected to vest, end of the period	4,095,070	2.16			1.21		8.47	38

During the three months ended March 31, ~~2021,~~2022, the Company granted ~~50,922~~approximately 1.2 million restricted stock units or RSUs to employees with a weighted average fair value of ~~$15.15~~$1.20 per RSU and total aggregate intrinsic value of ~~0.7~~$1.4 million. ~~NaNne of~~12,048 RSUs vested and 26,074 RSU's were forfeited during the ~~RSUs were vested as of~~three months ended March 31, ~~2021, and they had a weighted average remaining contractual life of 3.0 years.~~2022.

As of March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, there was an aggregate of ~~4.8~~2.1 million and ~~5.0~~3.4 million shares of common stock, respectively, available for grant under the 2020 Plan.

In April 2022, the Company adopted the MedAvail Holdings, Inc. 2022 Inducement Equity Incentive Plan or the Inducement Plan. The Inducement Plan reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April 8, 2022, the Company issued inducement awards to employees that included options to purchase 426,500 shares of Company common stock, and 426,500 RSUs. The inducement stock options have an exercise price of $1.96, and 25% of the shares vest on the one year anniversary of the date that employment commenced, and an additional one forty-eighth (1/48th) of the shares vest monthly thereafter. The inducement RSUs vest at one-third (1/3rd) of the shares on the first, second and third yearly anniversaries of March 1, 2022.

Warrants

During the three months ended March 31, ~~2021 0~~2022 no warrants were ~~issued.~~

~~On May 10, 2021,~~issued or exercised. There were 626,339 related party warrants ~~were exercised in exchange for issuing 465,496 shares~~outstanding as of ~~the Company's common stock, with total cash proceeds of $90 thousand.~~March 31, 2022.

NOTE 1112 - REVENUE AND SEGMENT REPORTING

Operating segments are the individual operations that the chief operating decision maker, ~~("CODM"),~~or CODM, who is our chief executive officer, reviews for purposes of assessing performance and making resource allocation decisions. The CODM currently receives the monthly management report which includes information to assess performance. The retail pharmacy services and pharmacy technology operating segments both engage in different business activities from which they earn revenues and incur expenses.

The Company has the following 2 reportable segments:

Retail Pharmacy Services Segment

Retail ~~pharmacy services~~Pharmacy Services segment revenue consists of products sold directly to consumers at the point of sale. MedAvail recognizes retail pharmacy ~~sales~~ revenue, net of taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer. The Company estimates revenue based on expected reimbursements from third-party payers (e.g., pharmacy benefit managers, insurance companies and governmental agencies) for dispensing prescription drugs. The estimates are based on all available information including historical experience and are updated to actual reimbursement amounts.

Pharmacy Technology Segment

The ~~pharmacy technology segment~~Pharmacy Technology Segment consists of sales and subscriptions of MedPlatform systems to customers. These agreements include providing the MedCenter prescription dispensing kiosk, software, and maintenance services. This generally includes either an initial lump sum

payment upon installation of the MedCenter with monthly payments for software and services following, or monthly payments for the MedCenter along with monthly payments for software and maintenance services for subscription agreements.

The following table presents ~~sales~~revenue and costs of ~~sales~~products sold and services by ~~segment:~~segment, in thousands:

Retail Pharmacy Services Pharmacy Technology Total
Three Months Ended March 31, 2021
Sales:
Pharmacy and hardware sales:
Retail pharmacy sales $ 3,418 $ 0 $ 3,418
Hardware 0 241 241
Subscription sales 0 122 122
Total pharmacy and hardware sales 3,418 363 3,781
Service sales:
Software 0 33 33
Maintenance and support 0 31 31
Installation 0 16 16
Professional services and other 0 166 166
Total service sales 0 246 246
Total sales 3,418 609 4,027
Cost of sales 3,329 378 3,707
Gross profit $ 89 $ 231 $ 320

Retail Pharmacy Services Pharmacy Technology Total
Three Months Ended March 31, 2020
Sales:
Pharmacy and hardware sales:
Retail pharmacy sales $ 1,297 $ 0 $ 1,297
Hardware 0 0 0
Subscription sales 0 105 105
Total pharmacy and hardware sales 1,297 105 1,402
Service sales:
Software 0 0 0
Maintenance and support 0 10 10
Installation 0 0 0
Professional services and other 0 0 0
Total service sales 0 10 10
Total sales 1,297 115 1,412
Cost of sales 1,338 94 1,432
Gross profit $ (41) $ 21 $ (20)


	Retail Pharmacy Services		Pharmacy Technology		Total
Three Months Ended March 31, 2022
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue	$	8,849	$	—	$	8,849
Hardware	—		56		56
Subscription	—		109		109
Total pharmacy and hardware revenue	8,849		165		9,014
Service revenue:
Software integration	—		—		—
Software	—		48		48
Maintenance and support	—		32		32
Installation	—		6		6
Professional services and other	—		14		14
Total service revenue	—		100		100
Total revenue	8,849		265		9,114
Cost of products sold and services	8,482		131		8,613
Segment gross profit	$	367	$	134	501
Operating Expense:
Pharmacy operations					3,929
General and administrative					6,535
Selling and marketing					2,313
Research and development					493
Total operating expense					13,270
Operating loss					$	(12,769)


	Retail Pharmacy Services		Pharmacy Technology		Total
Three Months Ended March 31, 2021
Revenue:
Pharmacy and hardware revenue:
Retail pharmacy revenue	$	3,418	$	—	$	3,418
Hardware	—		241		241
Subscription	—		122		122
Total pharmacy and hardware revenue	3,418		363		3,781
Service revenue:
Software integration	—		—		—
Software	—		33		33
Maintenance and support	—		31		31
Installation	—		16		16
Professional services and other	—		166		166
Total service revenue	—		246		246
Total revenue	3,418		609		4,027
Cost of products sold and services	3,329		378		3,707
Segment gross profit	$	89	$	231	320
Operating Expense:
Pharmacy operations					2,593
General and administrative					5,676
Selling and marketing					1,534
Research and development					168
Total operating expense					9,971
Operating loss					$	(9,651)

The following table presents assets and liabilities by ~~segment:~~segment, in thousands:


		Retail Pharmacy Services		Pharmacy Technology		Corporate		Total			Retail Pharmacy Services		Pharmacy Technology		Corporate		Total
March 31, 2021
March 31, 2022										March 31, 2022
Assets	Assets	$	6,852	$	5,414	$	47,272	$	59,538	Assets	$	16,323	$	6,661	$	4,708	$	27,692
Liabilities	Liabilities	$	2,374	$	2,300	$	2,783	$	7,457	Liabilities	$	6,705	$	4,183	$	10,189	$	21,077
December 31, 2020
December 31, 2021										December 31, 2021
Assets	Assets	$	6,012	$	5,547	$	57,772	$	69,331	Assets	$	13,641	$	5,222	$	19,280	$	38,143
Liabilities	Liabilities	$	2,203	$	3,422	$	2,639	$	8,264	Liabilities	$	5,618	$	3,567	$	9,885	$	19,070

The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the ~~assets:~~assets, in thousands:


		March 31,		December 31,			March 31,		December 31,
		2021		2020			2022		2021
Long-lived assets:	Long-lived assets:					Long-lived assets:
United States	United States	$	4,844	$	4,533	United States	$	8,383	$	7,675
Canada	Canada	256		$	501	Canada	420		555
Total long-lived assets	Total long-lived assets	$	5,100	$	5,034	Total long-lived assets	$	8,803	$	8,230

NOTE 12 - SUBSEQUENT EVENTS

On March 30, 2022, the Company entered into a Securities Purchase Agreement, or Purchase Agreement, with certain purchasers thereto, or the Investors. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Investors in a private placement, or the Private Placement, up to 47.1 million shares, or the Shares, of the Company’s Common Stock, and to issue warrants, or the Warrants, to purchase up to 23.5 million shares of Common Stock, or Warrant Shares. The Shares and the Warrants were or will be sold at 2 closings as further described below, at a price per share of $1.0625.

Each Investor purchasing Shares in the Private Placement was or will also be issued a Warrant to purchase that number of Warrant Shares equal to 50% of the number of Shares purchased under the Purchase Agreement by such Investor. The Warrants have a per share exercise price of $1.25 and will be exercisable by the holder at any time on or after the issuance date of the Warrant for a period of five years. If the Warrants were exercised in full by the Investors, the Company would receive additional gross proceeds of up to $29.4 million. In addition, the Warrant terms provide the Company with a call option to force the Warrant holders to exercise up to two-thirds of the warrant shares subject to each Warrant, with one-third of the Warrant Shares being callable beginning on each of the 12 month and 24 month anniversaries of the Warrant issuance dates, in each case until the expiration of the Warrants, and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. If the Company were to exercise the contingent call options, approximately $19.6 million in additional equity could be raised.

On April 4, 2022, the first closing of the Private Placement occurred, in which 37.6 million shares of Common Stock for $40.0 million in gross proceeds, and Warrants exercisable for up to 18.8 million Warrant Shares were sold and issued by the Company, and pursuant to which the Company received $40.0 million in gross proceeds, before deducting placement agent commissions and other offering expenses. A second and final closing is expected to occur in July 2022, subject to the satisfaction or wavier of certain conditions to closing, pursuant to which the Company shall sell and issue, and the Investors shall purchase, an additional 9.4 million shares of Common Stock for $10.0 million in additional gross proceeds and Warrants exercisable for up to 4.7 million Warrant Shares.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion in conjunction with our audited historical consolidated condensed financial statements for the year ended December 31, ~~2020,~~2021, which are included in the Annual Report on Form 10-K, filed with the ~~SEC~~Securities and Exchange Commission on March ~~31, 2021,~~29, 2022, and our unaudited consolidated condensedfinancial statements for the three months ended March 31, ~~2021~~2022 included elsewhere in this Quarterly Report on Form 10-Q. This Management's Discussion and Analysis of Financial Condition and Results of Operations contains statements that are forward-looking. These statements are based on current expectations and assumptions that are subject to risks, uncertainties and other factors. Actual results could differ materially because of the factors discussed below or elsewhere in this Quarterly Report on Form 10-Q. See Part II, Item 1A. "Risk Factors" of this Quarterly Report on Form 10-Q, and Part I, Item 1A. "Risk Factors" of the ~~2020~~2021 Form 10-K for the year ended December 31, ~~2020.~~2021. Unless otherwise indicated or the context otherwise requires, references herein to “MedAvail,” “MedAvail Holdings,” “we,” “us,” “our,” and the “Company” refers to MedAvail Holdings, Inc. and its subsidiaries.

Overview

We are a technology-enabled retail pharmacy technology and services company, ~~that is transforming full-service pharmacy.~~we have developed and commercialized an innovative self-service pharmacy, mobile application, kiosk, and drive-thru solution. Through our full-stack pharmacy technology platform, and personal one-on-one service, we bring pharmacy-dispensing capability to the point of care, resulting in lower costs, higher patient satisfaction, improved medication adherence, and better health outcomes.

We offer a unique, pharmacy technology solution which is anchored around our core technology called the MedAvail MedCenter™, or the MedCenter. The MedCenter enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and any other location where onsite prescription dispensing is desired. The MedCenter establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient while still providing real-time supervision by a pharmacist. Although ~~its~~our technology platform has broad application, we are currently focused on serving high-value Medicare members in the United States of America, or U.S.

We currently deploy the MedCenter solution through two distinct commercialization channels. First, we own and operate a full retail pharmacy business in the U.S. under the name SpotRx™, or SpotRx. The SpotRx pharmacy business is structured as a hub-and-spoke model where a central pharmacy supports and operates MedCenter kiosks embedded in medical clinics, usually in close proximity to the central pharmacy. The second commercialization channel is a direct ‘sell-to’ model, whereby we sell the MedCenter technology and subscriptions for the associated software directly to large healthcare providers and retailers for use within their own pharmacy operations.

The MedCenter kiosk works in tandem with our Remote Dispensing System®, or the Remote Dispensing System, which consists of customer-facing software for remote ordering of medications for pick-up at a MedCenter, or ~~free,~~ next day home delivery. Supporting ~~its~~our MedCenter kiosks and Remote Dispensing System is our back-end MedPlatform® Enterprise Software, or the MedPlatform Enterprise Software, which controls dispensing and MedCenter monitoring; and supporting Pharmacy Management System software, which allows connection to our supporting team of pharmacists and kiosk administrators.

Our kiosks come in two models: the M4 MedCenter and the M5 MedCenter. The M4 MedCenter kiosk is designed to fit in waiting rooms, hallways, and lobbies. The M5 MedCenter is a larger kiosk designed as a full pharmacy replacement with the ability to serve 3-4 customers simultaneously. It can also to be configured for drive through dispensing, similar to bank ATM drive through lanes.

Traditional retail pharmacies are built around a physical store front. In order to dispense medication, these stores must have a pharmacist onsite for all hours of operation. ~~Most~~Many pharmacies have reduced hours of operation based on customer purchasing patterns in order to contain labor cost, which results in further reduced consumer access. Furthermore, retail pharmacy wait times are typically 30 to 60 minutes or more, causing substantial delays for the consumer. During the COVID-19 pandemic, ~~most~~many people are looking to minimize the amount of physical contact that can lead to further disease contraction, especially for those most vulnerable, such as the elderly or those with compromised immune systems. Consequently, some patients are foregoing filling their prescribed medications, leading to declining health, increased healthcare costs and increased morbidity.

Components of Operating Results for the Three Months Ended March 31, ~~2021~~2022

We have never been profitable and ~~have~~we incurred operating losses in each year since inception. Our net losses were ~~$9.5~~$13.0 million and ~~$5.7~~$9.5 million for the three months ended March 31, ~~2021~~2022 and ~~2020,~~2021, respectively. As of March 31, ~~2021,~~2022, we had an accumulated deficit of ~~$157.7~~$205.1 million. Substantially all of our operating losses resulted from expenses incurred in connection with building out our retail pharmacy services operating footprint and from general and administrative costs associated with our operations.

We expect to incur significant additional expenses and operating losses for ~~at least~~ the ~~next two years~~foreseeable future as we initiate and continue the technology development, deployment of our MedCenter technology and adding personnel necessary to operate as a public company with rapidly growing

retail pharmacy operations in the United States. In addition, operating as a publicly traded company involves the hiring of additional financial and other personnel, upgrading our financial information systems and incurring costs associated with operating as a public company. We expect

that our operating losses will ~~lessen~~decrease and turn positive as we execute our growth strategies within ~~each of~~ our operating segments. If our management accelerates deployment into new states, operating losses could increase in the near-term, as ~~the~~ we grow and scale our ~~operations in new states;~~operations; we expect operating performance to turn positive once each state reaches sufficient scale in sales volume.

As of March 31, ~~2021,~~2022, we had cash and cash equivalents of ~~$47.6~~$5.3 million. We will continue to require additional capital to continue our technology development and commercialization activities and build out our pharmacy operations to serve our growing customer base. Accordingly, in November 2020 and April 2022 we completed the sale of additional equity through a private placement funding, where ~~the~~ we raised $83.9 million, and $40.0 million, respectively. Additionally, in June 2021 we entered into a term loan and borrowed $10.0 million. Although we believe the proceeds from the private placement represents sufficient funding to execute our current growth plan, due to market risks (as outlined in the "Risk Factors" section of this Quarterly Report on Form 10-Q), we may needWe expect to raise additional capital to continue ~~to fund our~~funding operations. The amount and timing of ~~our~~ future funding requirements will depend on many factors, including the pace and results of our growth strategy and capital market conditions. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop product candidates.

We have two reportable segments: Retail Pharmacy Services and Pharmacy Technology. These reportable segments are generally defined by how we execute our go-to-market strategy to sell products and services.

Overview of Retail Pharmacy Services Segment

The Retail Pharmacy Services operating segment operates as SpotRx, or the Pharmacy, a full-service retail pharmacy utilizing our automated pharmacy technology, primarily servicing Medicare patients in the United States. In operating SpotRx, we employ the pharmacy team, purchase the medications, and deploy our proprietary technology, the MedCenter, directly into the Medicare-focused clinics. This is an end-to-end turnkey solution.

Overview of Pharmacy Technology Segment

MedAvail Technologies develops and commercializes the MedCenter for direct sale or ~~lease~~subscription to third-party customers, including some of the world’s largest healthcare providers and systems, as well as large retail chains that provide full retail-pharmacy services using our technology.

Results of Operations for the Three Months Ended March 31, 2022

~~Sales~~Revenue – Retail Pharmacy and Hardware and Service

Retail pharmacy and hardware ~~sales~~revenue

Retail pharmacy ~~sales~~revenue from the ~~retail pharmacy services~~Retail Pharmacy Services segment are derived from sales of prescription medications and over-the-counter products to patients. Medications are sold and delivered by various methods including dispensing product directly from the MedCenter, patient pick up at MedAvail’s SpotRx pharmacy locations or home delivery of medications to patient residences. Hardware sales from the pharmacy technology segment are derived from either the sales or subscription of the MedCenter to customers.

Service ~~sales~~revenue

Services ~~sales~~revenue from the ~~pharmacy technology segment are~~Pharmacy Technology Segment is derived from installation and support services.

2021

~~Sales~~Revenue

Three Months Ended March 31, 2021 vs. 2020
2021 2020 Amount Change % Change
Pharmacy and hardware sales: (in thousands)
Retail pharmacy sales $ 3,418 $ 1,297 $ 2,121 164 %
Hardware 241 — 241 — %
Subscription sales 122 105 17 16 %
Total pharmacy and hardware sales 3,781 1,402 2,379 170 %
Service sales:
Software 33 — 33 — %
Maintenance and support 31 10 21 210 %
Installation 16 — 16 — %
Professional services and other 166 — 166 — %
Total service sales 246 10 236 2360 %
Total sales $ 4,027 $ 1,412 $ 2,615 185 %


	Three Months Ended March 31,				2022 vs. 2021
	2022		2021		Amount Change		% Change
Pharmacy and hardware revenue:	(in thousands)
Retail pharmacy revenue	$	8,849	$	3,418	$	5,431	159	%
Hardware	56		241		(185)		(77)	%
Subscription	109		122		(13)		(11)	%
Total pharmacy and hardware revenue	9,014		3,781		5,233		138	%
Service revenue:
Software integration	—		—		—		—	%
Software	48		33		15		45	%
Maintenance and support	32		31		1		3	%
Installation	6		16		(10)		(63)	%
Professional services and other	14		166		(152)		(92)	%
Total service revenue	100		246		(146)		(59)	%
Total revenue	$	9,114	$	4,027	$	5,087	126	%

During the three months ended March 31, ~~2021,~~2022, retail pharmacy and hardware ~~sales~~revenue increased ~~$2.4~~$5.2 million to ~~$3.8~~$9.0 million compared to the same period in ~~2020.~~2021. The $5.2 million increase was ~~primarily~~ due to a $5.4 million increase from volume growth in prescription ~~sales~~revenue at existing sites and additional sites launched in ~~Arizona, as well as growth~~Florida and Michigan throughout 2021 and continuing into 2022, offset by the decrease in hardware revenue from ~~newly launched sites in Arizona, California and Michigan.~~the first quarter 2021.

During the three months ended March 31, ~~2021, services sales increased $0.24~~2022, service revenue decreased $0.15 million to ~~$0.25~~$0.10 million compared to the same period in 2020. The increase was due to the related increase in pharmacy and hardware sales, and professional services associated with contracted software integration work enabling a large health system customer to fully integrate their backend pharmacy management system with our back-end MedPlatform® Enterprise Software.2021.

Cost of ~~Sales – Pharmacy~~Products Sold and ~~Hardware and Service~~Services

~~Pharmacy~~Retail pharmacy and hardware cost of ~~sales~~products sold

Cost of ~~sales~~products sold consists primarily of prescription medications, and other over-the-counter health products; and costs ~~incurred to manufacture~~associated with MedCenters sold to third-party customers.

Service ~~cost of sales~~costs

~~Cost of sales~~Service costs consists primarily of costs incurred to install and maintain MedCenters at third-party customer locations.

Costs of Products and Services


	Three Months Ended March 31,				2022 vs. 2021
	2022		2021		Amount Change		% Change
Retail pharmacy and hardware cost of products sold:	(in thousands)
Prescription drugs	$	7,856	$	3,060	$	4,796	157	%
Shipping	625		270		355		131	%
Hardware	56		150		(94)		(63)	%
Depreciation	26		46		(20)		(43)	%
Total retail pharmacy and hardware cost of products sold	8,563		3,526		5,037		143	%
Service costs:
Professional services	1		142		(141)		(99)	%
Maintenance and support services	45		28		17		61	%
Installation services	4		11		(7)		(64)	%
Total service costs	50		181		(131)		(72)	%
Total cost of products sold and services	$	8,613	$	3,707	$	4,906	132	%

2122

~~Costs of sales~~

Three Months Ended March 31, 2021 vs. 2020
2021 2020 Amount Change % Change
Retail pharmacy and hardware cost of sales: (in thousands)
Prescription drugs $ 3,060 $ 1,274 $ 1,786 140 %
Shipping 270 63 207 329 %
Hardware 150 — 150 — %
Depreciation 46 48 (2) (4) %
Total retail pharmacy and hardware cost of sales 3,526 1,385 2,141 155 %
Service cost of sales:
Professional services 142 — 142 — %
Maintenance and support services 28 34 (6) (18) %
Installation services 11 13 (2) (15) %
Total service cost of sales 181 47 134 285 %
Total cost of sales $ 3,707 $ 1,432 $ 2,275 159 %

During the three months ended March 31, ~~2021,~~2022, retail pharmacy and hardware cost of ~~sales~~products sold increased ~~$2.1~~$5.0 million to ~~$3.5~~$8.6 million compared to the same period in ~~2020.~~2021. The increase was primarily due to costs associated with volume growth in prescription sales at existing sites and additional sites launched in ~~the remaining period in 2020~~Florida and Michigan throughout 2021 ~~in Arizona, California~~ and ~~Michigan.~~continuing into 2022. Shipping costs, related to our home delivery service via third-party courier, increased ~~$0.2~~$0.4 million compared to the same period in ~~2020. This increase is due to increased utilization of the service due to higher telehealth clinic visits caused by the Covid-19 pandemic.~~2021.

During the three months ended March 31, ~~2021,~~2022, service ~~cost of sales increased $0.1 million to $0.2 million compared to~~costs were reasonably consistent with the same period in 2020. The increase was due primarily to costs associated with contracted software integration work enabling a large health system customer to fully integrate their backend pharmacy management system with our MedPlatform® Enterprise Software.the prior year.

Pharmacy Operations

Pharmacy operations

~~Pharmacy operations costs~~ consist of costs incurred to operate retail pharmacies ~~including pharmacy labor costs, rent~~ and ~~utilities, and pharmacy license fees.~~our call center. Wages and salaries consist of compensation costs incurred for all pharmacy operations related employees and contractors including bonuses, health plans, severance, and contractor costs. Facility expenses consist of rent and utilities directly associated with our pharmacy operations.

Other pharmacy operations expenses consist of supply costs, and other costs.

Depreciation of property, plant and equipment includes depreciation on MedCenters, IT equipment, leasehold improvements, general plant and equipment, software, office furniture and equipment and vehicles. Amortization of intangible assets consists of amortization of ~~intellectual property, website and~~ mobile applications and software.


		Three Months Ended March 31,				2021 vs. 2020					Three Months Ended March 31,				2022 vs. 2021
		2021		2020		Amount Change		% Change			2022		2021		Amount Change		% Change
Pharmacy operations expenses:	Pharmacy operations expenses:	(in thousands)								Pharmacy operations expenses:	(in thousands)
Wages and salaries	Wages and salaries	$	1,448	$	835	$	613	73	%	Wages and salaries	$	2,959	$	2,135	$	824	39	%
Other pharmacy operations expenses		221		60		161		268	%
Rent, utilities, and other										Rent, utilities, and other	502		171		331		194	%

Depreciation of property, plant and equipment	Depreciation of property, plant and equipment	208		157		51		32	%	Depreciation of property, plant and equipment	227		208		19		9	%

Amortization of intangible assets	Amortization of intangible assets	34		37		(3)		(8)	%	Amortization of intangible assets	122		34		88		259	%
Repairs and maintenance										Repairs and maintenance	119		45		74		164	%
Total pharmacy operations expenses	Total pharmacy operations expenses	$	1,911	$	1,089	$	822	75	%	Total pharmacy operations expenses	$	3,929	$	2,593	$	1,336	52	%

During the three months ended March 31, ~~2021,~~2022, pharmacy operations expenses increased ~~$0.8~~$1.3 million to ~~$1.9~~$3.9 million compared to the same period in ~~2020.~~2021. This increase was primarily due to ~~the opening of four~~having one additional central pharmacy ~~locations~~location in 2022 compared to the ~~remaining~~same period in ~~2020, including three in California and one in Michigan.~~2021. Additionally, volume growth continued to ramp at existing pharmacy locations, ~~in Arizona,~~thus increasing pharmacy personnel and supplies, ~~during the remaining period in 2020 and 2021,~~ resulting in increased wages, salaries, and operating costs.

Amortization of intangible assets has increased as a result of deploying internally developed software in our pharmacy operations.

General and ~~administrative~~Administrative

General and administrative expenses consist of personnel costs, facility expenses and expenses for outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, benefits and share-based compensation. Facility expenses consist of rent and other related ~~costs.~~costs specific to our corporate and technology activities. Corporate insurance, office supplies and technology expenses are also captured within general and administrative expenses. We incurred and expect to incur additional expenses as a result of ~~becoming~~being a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.

We have a stock option plan whereby awards are granted to certain of our employees. The fair value of the stock options and restricted stock units granted by us to our employees is recognized as compensation expense on a straight-line basis over the applicable vesting period. We measure the fair value of the stock options using the Black-Scholes option pricing model as of the grant ~~date/measurement~~ date. Shares issued upon the exercise of stock options and vesting of restricted stock units are new shares. We estimate forfeitures based on historical experience and expense related to awards is adjusted over the term of the awards to reflect their probability of vesting. All fully vested awards are ~~fully~~ expensed.

Three Months Ended March 31, 2021 vs. 2020
2021 2020 Amount Change % Change
General and administrative expenses: (in thousands)
Wages and salaries $ 3,756 $ 2,088 $ 1,668 80 %
Professional services 1,045 158 887 561 %
Rent and utilities 418 355 63 18 %
Office and IT supplies 293 312 (19) (6) %
Insurance 458 45 413 918 %
Share-based compensation 260 84 176 210 %
Travel and other employee expenses 153 196 (43) (22) %
Other general and administrative expenses 132 262 (130) (50) %
Total general and administrative expenses $ 6,515 $ 3,500 $ 3,015 86 %


	Three Months Ended March 31,				2022 vs. 2021
	2022		2021		Amount Change		% Change
General and administrative expenses:	(in thousands)
Wages and salaries	$	3,488	$	2,918	$	570	20	%
Professional services	834		1,045		(211)		(20)	%
Share-based compensation	569		260		309		119	%
Insurance	508		458		50		11	%
Software licenses and support	360		185		175		95	%
Rent, utilities, and other	569		539		30		6	%


Office and IT supplies	102		75		27		36	%
Travel and other employee expenses	72		155		(83)		(54)	%
Depreciation of property, plant and equipment	33		41		(8)		(20)	%
Total general and administrative expenses	$	6,535	$	5,676	$	859	15	%

During the three months ended March 31, ~~2021,~~2022, general and administrative costs increased approximately ~~$3.0~~$0.9 million to $6.5 million compared to the same period in ~~2020.~~2021. This increase was primarily due to hiring additional administrative staff, increased share based compensation, as well as other investments necessary for our growth ~~and becoming a public company. Additionally, increases in other general expenses, such~~ as ~~director and officer insurance, auditor fees, and legal fees was also partly a consequence of becoming~~ a public company.

Selling and ~~marketing~~Marketing

Selling and marketing expenses consist of personnel costs, marketing and advertising costs, ~~personnel costs,~~and marketing related expenses for outside professional services. Wages and salaries consist of compensation costs incurred for all selling and marketing employees including our in clinic customer account managers, and contractors including bonuses, health plans, ~~severance,~~ and ~~contractor costs.~~severance.


		Three Months Ended March 31,				2021 vs. 2020					Three Months Ended March 31,				2022 vs. 2021
		2021		2020		Amount Change		% Change			2022		2021		Amount Change		% Change
Selling and marketing expenses:	Selling and marketing expenses:	(in thousands)								Selling and marketing expenses:	(in thousands)
Wages and salaries	Wages and salaries	$	1,212	$	550	$	662	120	%	Wages and salaries	$	2,094	$	1,362	$	732	54	%
Travel and other employee expenses										Travel and other employee expenses	130		38		92		242	%
Marketing	Marketing	129		92		37		40	%	Marketing	74		129		(55)		(43)	%
Travel and other employee expenses		31		37		(6)		(16)	%
Other selling and marketing expenses	Other selling and marketing expenses	5		24		(19)		(79)	%	Other selling and marketing expenses	15		5		10		200	%
Total selling and marketing expenses	Total selling and marketing expenses	$	1,377	$	703	$	674	96	%	Total selling and marketing expenses	$	2,313	$	1,534	$	779	51	%

During the three months ended March 31, ~~2021,~~2022, selling and marketing costs increased approximately ~~$0.7~~$0.8 million to ~~$1.4~~$2.3 million compared to the same period in ~~2020.~~2021. This increase was primarily due to personnel related costs associated with hiring additional Clinic Account Managers (CAMs) and Regional Directors, which directly support the ~~medical clinic’s~~ staff and patients at the medical clinics where we are deployed.

Research and ~~development~~Development

Research and development expenses represent costs incurred to develop and innovate on our MedCenter platform technology, including development work on hardware, software and supporting information technology infrastructure. Wages and salaries consist of compensation costs incurred for research and development employees and contractors including bonuses, health plans, severance, and contractor costs.

We recognize hardware development costs as they are incurred. When hardware is constructed for use by customers, costs are capitalized after technological feasibility is achieved and expensed before technological feasibility is achieved. Costs of hardware completed but not yet placed in service are capitalized as equipment (a long-lived asset) on the consolidated condensed balance sheets. Costs of hardware completed and placed in service with customers are capitalized as equipment and depreciated (expensed) over the estimated useful life of the equipment.


	Three Months Ended March 31,				2022 vs. 2021
	2022		2021		Amount Change		% Change
Research and development expenses:	(in thousands)
Wages and salaries	$	191	$	167	$	24	14	%
Other expenses	302		1		301		30,100	%
Total research and development expenses	$	493	$	168	$	325	193	%

Software development costs are accrued and expensed based on ASC 985, which is for software that we intend to sell (in conjunction with related hardware). Any software development costs that are incurred prior to the point where the project has demonstrated technological feasibility are expensed as they are incurred. Once technological feasibility has been established, most development costs are capitalized. Once development is complete and the software is made available for release to customers, capitalization no longer is appropriate because any remaining costs are considered ongoing maintenance and support. These are expensed as they are incurred.

Three Months Ended March 31, 2021 vs. 2020
2021 2020 Amount Change % Change
Research and development expenses: (in thousands)
Wages and salaries $ 167 $ 125 $ 42 34 %
Materials — 86 (86) (100) %
Other expenses 1 4 (3) (75) %
Total research and development expenses $ 168 $ 215 $ (47) (22) %

During the three months ended March 31, ~~2021,~~2022, research and development costs ~~decreased~~increased approximately ~~$0.05~~$0.3 million. This ~~decrease~~increase was primarily due to ~~completion of certain development work related~~ongoing product improvement activities, including efforts to integrate our ~~M5 MedCenter technology in 2020.~~

~~Other gain (loss)~~

During the three months ended March 31, 2021, other gain (loss) included a gain of $0.16 million from PPP loan forgiveness. MedAvail received forgiveness approval of the loan on March 30, 2021 in accordanceMedPlatform® Enterprises Software with the ~~terms of the CARES Act.~~EPIC pharmacy management system.

Interest ~~income~~Income and ~~expense~~Expense

Interest expense consists of accrued interest on outstanding debt and is payable ~~upon the maturity date.~~monthly.


		Three Months Ended March 31,				2021 vs. 2020					Three Months Ended March 31,				2022 vs. 2021
		2021		2020		Amount Change		% Change			2022		2021		Amount Change		% Change
Interest income:	Interest income:									Interest income:	(in thousands)
Interest income	Interest income	$	40	$	8	$	32	400	%	Interest income	$	1	$	40	$	(39)	(98)	%
Total interest income	Total interest income	$	40	$	8	$	32	400	%	Total interest income	$	1	$	40	$	(39)	(98)	%
Interest expense:	Interest expense:									Interest expense:
Interest expense	Interest expense	$	(2)	$	(179)	$	177	(99)	%	Interest expense	$	(254)	$	(2)	$	(252)	12,600	%
Total interest expense	Total interest expense	$	(2)	$	(179)	$	177	(99)	%	Total interest expense	$	(254)	$	(2)	$	(252)	12,600	%

During the three months ended March 31, ~~2021,~~2022, interest expense ~~decreased~~increased compared to the same period in ~~2020~~2021 due to ~~a convertible note that was outstanding during the first quarter in 2020 and settled in November 2020. On March 24, 2016, MedAvail and a significant customer and investor entered~~entering into a subordinated secured convertible promissory five-year note agreement for $10.0 million or the Convertible Note. This Convertible Note was convertible into common shares at the option holder’s request. The Convertible Note, including accrued interest, was repaidterm loan in ~~its entirety on November 17, 2020.~~June 2021. For more detail on outstanding debt and associated maturities, see Note 78 to the unaudited consolidated condensed financial statements presented elsewhere in this Quarterly Report on Form 10-Q.

Liquidity and Capital Resources

Sources of Liquidity

Since inception through March 31, ~~2021,~~2022, our operations have been financed primarily by net cash proceeds from the sale of stock from private placements, the sale of redeemable preferred stock and debt. As of March 31, ~~2021,~~2022, we had ~~$47.6~~$5.3 million in cash and cash equivalents and an accumulated deficit of ~~$157.7~~$205.1 million. ~~Although~~We added to our liquidity resources in 2021 through a senior secured term loan facility with Silicon Valley Bank or the Loan Agreement, pursuant to which we ~~believe~~have borrowed $10.0 million in aggregate initial term loans. In April 2022, we completed a private placement, pursuant to which we received $40.0 million in gross proceeds before deducting placement agent commissions and other offering expenses. An additional $10.0 million in gross proceeds is expected to close on July 1, 2022, subject to the satisfaction or waiver of certain conditions to closing.

In connection with the private placement, we issued callable warrants in April 2022 and expect to issue additional callable warrants in July 2022. The warrant call option is exercisable by us beginning on each of the 12 month and 24 month anniversaries of the warrant issuance dates and subject to the satisfaction of certain pricing conditions relating to the trading of our ~~cash~~shares. If the warrants are exercised in full by the Investors, we would receive additional gross proceeds of up to $29.4 million. If we exercise our call option, then we could raise up to an additional $19.6 million.

Management is also exploring additional sources of financing, the success of which is dependent on market conditions. Management has concluded that the aforementioned conditions, including the ongoing uncertainty related to the negative impacts of the COVID-19 pandemic and ~~cash equivalents are sufficient~~the uncertainties related to the conflict in Ukraine resulting from the military actions of Russia, including on the global economy and our supply chain, raise substantial doubt about our ability to continue as a going concern within 12 months from the date of issuance of the financial statements. Our plans to address this uncertainty include raising additional funding, ~~to execute our current growth plan, due to market risks (as outlined in the "Risk Factors" section of this Quarterly Report on Form 10-Q) and opportunities,~~as necessary, through public or private equity or debt financings.

However, we may ~~need~~not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if we issue equity securities to raise additional ~~capital~~funds, our existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to ~~continue to fund our operations. The amount and timing of its future funding requirements will depend on many factors, including the pace and results~~those of our ~~growth strategy and capital market conditions.~~existing stockholders. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates. Our management actively evaluates matters of liquidity and growth capital needs, including evaluating debt and equity as sources of growth capital with a focus on lower overall weighted average cost of capital and favorable financing terms. Our primary uses of liquidity are operating activities, capital expenditures, and lease payments.

Cash Flows

The following table summarizes our cash flows for the three months ended March 31, ~~2021~~2022 and ~~2020:~~2021:


		Three Months Ended March 31,				2021 vs. 2020					Three Months Ended March 31,				2022 vs. 2020
		2021		2020		Amount Change		% Change
		(in thousands)
(In thousands)										(In thousands)	2022		2021		Amount Change		% Change
Cash used in operating activities	Cash used in operating activities	$	(9,830)	(5,899)		$	(3,931)	67	%	Cash used in operating activities	$	(13,264)	$	(9,830)	$	(3,434)	35	%
Cash used in investing activities	Cash used in investing activities	(712)		(203)		(509)		251	%	Cash used in investing activities	(852)		(712)		(140)		20	%
Cash provided by financing activities		189		815		(626)		(77)	%
Cash (used in) provided by financing activities										Cash (used in) provided by financing activities	(23)		189		(212)		(112)	%
Net decrease in cash and cash equivalents, and restricted cash	Net decrease in cash and cash equivalents, and restricted cash	$	(10,353)	$	(5,287)	$	(5,066)	96	%	Net decrease in cash and cash equivalents, and restricted cash	$	(14,139)	$	(10,353)	$	(3,786)	37	%

Operating Activities

During the three months ended March 31, ~~2021,~~2022, cash used in operating activities increased ~~$3.9~~$3.4 million to ~~$9.8~~$13.3 million compared to the same period in ~~2020.~~2021. The increase was primarily due to an increase in inventory, operating expenses from wages and salaries, and costs attributable to the launch and growth of our retail pharmacy operations in Arizona, California, ~~and~~ Michigan, and ~~becoming~~Florida, and operating as a public company.

Investing Activities

During the three months ended March 31, ~~2021,~~2022, cash used in investing activities increased ~~$0.5~~$0.1 million to ~~$0.7~~$0.9 million compared to the same period in ~~2020.~~2021. The increase was primarily due to an increase in investment in property, plant and equipment and intangible assets associated with investments in ~~retail pharmacy services~~Retail Pharmacy Services operations in Arizona, California, Michigan, and ~~Michigan.~~Florida.

Financing Activities

During the three months ended March 31, ~~2021,~~2022, cash provided by financing activities decreased ~~$0.6~~$0.2 million to ~~$0.2~~$0.0 million compared to the same period in ~~2020. The decrease~~2021. During the three months ended March 31, 2021, the activity was primarily from the issuance of common stock due to ~~issuance~~the exercise of ~~preferred stock in the first quarter of 2020, without~~options and warrants, with no similar activity induring the ~~first quarter of 2021.~~three months ended March 31, 2022.

Critical Accounting ~~Policies and~~ Estimates

There were no significant changes in our critical accounting ~~policies~~estimates in the three months ended March 31, ~~2021,~~2022, from those previously disclosed in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, filed with the SEC on March ~~31, 2021.~~29, 2022.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements, see Part II, Item 78, Note 5 of our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, filed with the SEC on March ~~31, 2021,~~29, 2022, and Note 3:4: "Recent Accounting Pronouncements" in the notes to our unaudited consolidated condensed financial statements included elsewhere in this Quarterly Report Form 10-Q.

2526

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, our disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting

There have not been any changes in our internal control over financial reporting (as such term is defined in Rules ~~13a15(f)~~13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, ~~2021~~2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

2627

PART II

Item 1. Legal Proceedings

~~Following MYOS Rens Technology Inc.’s, or MYOS’s~~The information set forth under the heading “Legal” in Note 10, Commitments and ~~MedAvail, Inc.’s, or MAI's, announcement~~Contingencies, in Part I, Item 1 of the execution of the Merger Agreement on June 30, 2020, MYOS received separate litigation demands from purported MYOS stockholders on September 16, 2020 and October 20, 2020, respectively seeking certain additional disclosures in the Form S-4 Registration Statement filed with the Securities and Exchange Commission on September 2, 2020, collectively, the Demands. Thereafter, on September 23, 2020, a complaint regarding the transactions contemplated within the Merger Agreement was filed in the Supreme Court of the State of New York, County of New York, captioned Faasse v. MYOS RENS Technology Inc., et. al., Index No.: 654644/2020 (NY Supreme Ct., NY Cnty., September 23, 2020), or the New York Complaint. On October 12, 2020, a second complaint regarding the transactions was filed in the District Court of Nevada, Clark County Nevada, captioned Vigil v. Mannello, et. al., Case No. A-20-822848-C, or the Nevada Complaint, and together with the New York Complaint, the Complaints, and collectively with the Demands, the Litigation.

MYOS and MAI believe that the claims asserted in the Litigation are without merit, and believe that the Form S-4 Registration Statement disclosed all material information concerning the Merger and no supplemental disclosure is required under applicable law. However, in order to avoid the risk of the Litigation delaying or adversely affecting the Merger and to minimize the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, MYOS determined to voluntarily supplement the Form S-4 Registration Statement as described in the Currentthis Quarterly Report on Form 8-K on November 2, 2020. Subsequently, the Nevada Complaint and the New York Complaint were voluntarily dismissed. The remainder of the Litigation remains outstanding. MYOS and MAI specifically deny all allegations in the Litigation and/or that any additional disclosure was or10-Q is ~~required.~~incorporated herein by reference.

Item 1A. Risk Factors

~~In addition to~~There have been no material changes from the ~~other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the~~risk factors ~~discussed below as well as~~disclosed in Part I, Item IA1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, ~~2020,~~2021, or the “2021 Annual Report, filed with the ~~SEC~~Securities and Exchange Commission on March ~~31,~~29, 2022. The risk factors described in our 2021 ~~which could materially affect our business, financial condition or operating results. The risks described~~Annual Report, as well as other information set forth in this Quarterly Report on Form 10-Q, could materially adversely affect our business, financial condition, results of operations and ~~in our 2020 Annual Report on Form 10-K~~prospects, and should be carefully considered. The risks and uncertainties that we face, however, are not limited to those described in the ~~only risks we face.~~2021 Annual Report. Additional risks and uncertainties not ~~currently~~presently known to us or that we currently ~~deem~~believe to be immaterial ~~also~~ may ~~materially~~also adversely affect our business ~~financial condition or operating results.~~

~~Risks Related to Ownership of the Company’s Securities~~

If we raise capital through the sale of shares of our common stock, convertible securities or debt in the future, your ownership in us could be diluted and restrictions could be imposed on our business.

We may issue shares of our common stock or securities convertible into or exchangeable for our common stock to raise additional capital in the future. To the extent we issue such securities, our stockholders may experience substantial dilution and the trading price of our ~~common stock could decline. If we obtain funds through a credit facility or through the issuance of debt or preferred~~ securities, such debt or preferred securities could have rights senior to your rights as a common stockholder, which could impair the value of our common stock. The terms of any such financing may also include restrictive covenants, such as limitations on our ability to incur additional debt and certain operating restrictions that could adversely impact our ability to conduct business.

~~We have not paid dividends~~particularly in ~~the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the value of our stock.~~

We have never paid dividends and do not anticipate paying dividends in the foreseeable future. The payment of dividends will depend on our earnings, capital requirements, financial condition, prospects and other factors our board of directors may deem relevant. If we do not pay dividends, our stock may be less valuable because a return on your investment will only occur if our stock price appreciates and you sell our common stock thereafter.

~~Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.~~

Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock. In addition, the sale of substantial amounts

of our common stock could adversely impact its trading price. The sale or the availability for sale of a large number of shares of our common stock in the public market could cause the price of our common stock to decline.

If securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our stock, our stock price and trading volume could decline.

~~The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If any~~light of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our target operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

~~An active trading market may not develop for our securities or what the market price of our securities will be and as a result it may be difficult for you to sell your shares of our securities.~~

Although our common stock is listed on The Nasdaq Capital Market under the symbol “MDVL”, an active trading market for our common stock may never develop or be sustained. You may not be able to sell your shares quickly or at the market price if trading in shares of our securities is not active. Further, an inactive market may also impair our ability to raise capital by selling shares of our securities and may impair our ability to enter into strategic partnerships or acquire companies or products by using shares of our securities as consideration, which could have a material adverse effect on our business, financial condition, and results of operations.

~~The market price and trading volume of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.~~

The market price and trading volume of our common stock are likely to be highly volatile and may fluctuate substantially in response to, among other things, the risk factors described in this prospectus and other factors, many of which are beyond our control, including:

•~~changes in analysts’ estimates, investors’ perceptions, recommendations by securities analysts or our failure to achieve analysts’ estimates;~~

•~~quarterly variations in our or our competitors’ results of operations;~~

•~~the impact~~fast-changing nature of the COVID-19 pandemic, ~~on us;~~

•~~periodic fluctuations in our revenue, which could be due in part~~containment measures and the related impacts to ~~the way in which we recognize revenue;~~

•~~the financial projections we may provide to the public, any changes in these projections or our failure to meet these projections;~~

•~~general market conditions~~economic and ~~other factors unrelated to our~~ operating ~~performance or the operating performance of our competitors;~~conditions.

•~~changes in reimbursement by current or potential payors;~~

•~~changes in operating performance and stock market valuations of other technology companies generally, or those in the telehealth, pharmaceutical, biotechnology industries in particular;~~

•~~actual or anticipated changes in regulatory oversight of our products;~~

•~~the loss of key personnel, including changes in our board of directors and management;~~

•~~product recalls or other problems associated with our products;~~

•~~legislation or regulation of our market;~~

•~~lawsuits threatened or filed against us, including litigation by current or former employees alleging wrongful termination, sexual harassment, whistleblower or other claims;~~

•~~the announcement of new products or product enhancements by us or our competitors;~~

•~~announced or completed acquisitions of businesses or technologies by us or our competitors~~

•~~announcements related to patents issued to us or our competitors and related litigation; and~~

•~~developments in our industry.~~

Fluctuations in our stock price, volume of shares traded, and changes in our market valuations may make our stock less attractive to certain investors. In the past, stockholders have filed securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business, and adversely affect our business, results of operations, financial condition, reputation and cash flows. These factors may materially and adversely affect the market price of our common stock.

~~Anti-takeover provisions in our amended and restated certificate of incorporation and bylaws, and Delaware law, could discourage a change in control of our company or a change in our management.~~

~~Our amended and restated certificate of incorporation and bylaws contain provisions that might enable our management to resist a takeover. These provisions include:~~

•~~a classified board of directors;~~

•~~advance notice requirements applicable to stockholders for matters to be brought before a meeting of stockholders and requirements as to the form and content of a stockholders’ notice;~~

•~~a supermajority stockholder vote requirement for amending certain provisions of our amended and restated certificate of incorporation and bylaws;~~

•~~the right to issue preferred stock without stockholder approval, which could be used to dilute the stock ownership of a potential hostile acquirer;~~

•~~allowing stockholders to remove directors only for cause;~~

•~~a requirement that the authorized number of directors may be changed only by resolution of the board of directors;~~

•allowing all vacancies, including newly created directorships, to be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum, except as otherwise required by law;

•~~a requirement that our stockholders may only take action at annual or special meetings of our stockholders and not by written consent;~~

•~~limiting the forum to Delaware for certain litigation against us; and~~

•limiting the persons that can call special meetings of our stockholders to our board of directors, the chairperson of our board of directors, the chief executive officer or the president (in the absence of a chief executive officer).

These provisions might discourage, delay or prevent a change in control of our company or a change in our management. The existence of these provisions could adversely affect the voting power of holders of common stock and limit the price that investors might be willing to pay in the future for shares of our common stock. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any “interested” stockholder for a period of three years following the date on which the stockholder became an “interested” stockholder.

~~Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.~~

As of April 16, 2021, our directors, officers and each stockholder holding 5% or more of our outstanding common stock and their affiliates beneficially owned approximately 80.4% of our outstanding common stock in the aggregate. Therefore, these stockholders will have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders. This concentration of ownership may have the effect of delaying or preventing a change in control, might adversely affect the market price of our common stock and may not be in the best interests of our other stockholders.

~~As a smaller reporting company, we are subject to scaled disclosure requirements that may make it more challenging for investors to analyze our results of operations and financial prospects.~~

Currently, we are a “smaller reporting company,” as defined by Rule 12b-2 of the Exchange Act. As a “smaller reporting company,” we are able to provide simplified executive compensation disclosures in our filings and have certain other decreased disclosure obligations in our filings with the SEC, including being required to provide only two years of audited financial statements in annual reports. Consequently, it may be more challenging for investors to analyze our results of operations and financial prospects.

Furthermore, we are a non-accelerated filer as defined by Rule 12b-2 of the Exchange Act, and, as such, are not required to provide an auditor attestation of management’s assessment of internal control over financial reporting, which is generally required for SEC reporting companies under Section 404(b) of the Sarbanes-Oxley Act. Because we are not required to, and have not, had our auditors provide an attestation of our management’s assessment of internal control over financial reporting, a material weakness in internal controls may remain undetected for a longer period.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

3128

Item 6. Exhibits

Incorporated by Reference
Exhibit Number Description Form Exhibit Filing Date
3.1
Amended and Restated Certificate of Incorporation of the Registrant
8-K 3.1 November 18, 2020
3.2
Amended and Restated Bylaws of the Registrant
8-K 3.2 November 18, 2020
4.1
Form of Common Stock Purchase Warrant issued by MedAvail, Inc.
8-K 4.1 November 18, 2020
4.2
Amended and Restated Investors’ Rights Agreement by and among the Registrant, MedAvail, Inc., and certain stockholders, dated October 9, 2020
S-4/A 4.9 October 9, 2020
4.3
Form of Common Stock Purchase Warrant issued by the Registrant to H.C. Wainwright & Co., LLC or its affiliates
8-K 4.3 November 18, 2020
10.1#
Form of Indemnification Agreement between the Registrant and each director and executive officer of the Registrant
8-K 10.15 November 18, 2020
10.2#
MedAvail Holdings, Inc. 2020 Equity Incentive Plan and related form agreements
8-K 10.11 November 18, 2020
10.3#
MedAvail Holdings, Inc. 2020 Employee Stock Purchase Plan
8-K 10.12 November 18, 2020
10.4#
MedAvail, Inc. 2012 Equity Incentive Plan, as amended, and related form agreements
8-K 10.13 November 18, 2020
10.5#
MedAvail, Inc. 2018 Equity Incentive Plan and related form agreements
8-K 10.14 November 18, 2020
10.6
Product Distribution Agreement, dated October 31, 2018, by and between MedAvail Pharmacy Inc. and Priority Healthcare Distribution, Inc.
S-4 10.21 September 3, 2020
10.7§
Pharmacy Provider Agreement, dated September 11, 2017, by and between MedAvail Pharmacy Inc. and Express Scripts, Inc.
S-4 10.23 September 3, 2020
10.8§
Manufacturing and Supply Agreement, dated August 17, 2020, by and between MedAvail Technologies Inc. and KITRON TECHNOLOGIES
S-4 10.24 September 3, 2020
10.9
Industrial Lease, dated August 13, 2012, by and between MedAvail Technologies Inc. and The Great-West Life Assurance Company and 801611 Ontario Limited, as amended on February 11, 2019
S-4 10.8 September 3, 2020
10.10#§
Offer Letter, dated November 1, 2012, by and between MedAvail, Inc. and Ed Kilroy
S-4 10.15 September 3, 2020
10.11#§
Offer Letter, dated December 30, 2019, by and between MedAvail, Inc. and Ryan Ferguson
S-4 10.16 September 3, 2020
10.12#§
Offer Letter, dated May 16, 2018, by and between MedAvail, Inc. and William Misloski
S-4 10.17 September 3, 2020
10.13#§
Offer Letter, dated May 7, 2019, by and between MedAvail, Inc. and David Rawlins
S-4 10.18 September 3, 2020
10.14#§
Offer Letter, dated June 20, 2019, by and between MedAvail, Inc. and Neil Prezioso
S-4 10.19 September 3, 2020
31.1*
Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*
Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**
Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

~~Incorporated by Reference~~

~~Exhibit Number~~

~~Description~~

~~Form~~

~~Exhibit~~

~~Filing Date~~

101*

~~Inline XBRL Document Set for the consolidated condensed financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q~~

104*

~~Inline XBRL for the cover page of this Quarterly on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set~~

Incorporated by Reference

Exhibit Number

Description

Form

Exhibit

Filing Date

4.1

Form of Common Stock Purchase Warrant issued by MedAvail, Inc.

8-K

4.1

November 18, 2020

4.2

Amended and Restated Investors’ Rights Agreement by and among the Registrant, MedAvail, Inc., and certain stockholders, dated October 9, 2020

S-4/A

4.9

October 9, 2020

4.3

Form of Common Stock Purchase Warrant issued by the Registrant to H.C. Wainwright & Co., LLC or its affiliates

8-K

4.3

November 18, 2020

4.4

Securities Purchase Agreement, dated as of March 30, 2022

8-K

10.1

April 4, 2022

4.5

Registration Rights Agreement, dated as of March 30, 2022

8-K

10.2

April 4, 2022

4.6

Form of Warrant

8-K

10.3

April 4, 2022

10.1#§

Offer Letter by and between the Registrant and Mark Doerr

8-K

10.1

January 11, 2022

10.2#§

Change of Control and Severance Agreement by and between the Registrant and Mark Doerr

8-K

10.2

January 11, 2022

10.3#§

Transition Services Agreement between the Company and Ed Kilroy

8-K

10.3

January 11, 2022

10.4#§

Offer Letter between the Company and Steven Hess

8-K

10.1

February 22, 2022

10.5#§

Change of Control and Severance Agreement between the Company and Steven Hess

8-K

10.2

February 22, 2022

10.6#

MedAvail Holdings, Inc. 2022 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements.

8-K

10.1

April 8, 2022

31.1*

Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*

Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1**

Certifications of Chief Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101*

Inline XBRL Document Set for the consolidated condensed financial statements and accompanying notes in Part I, Item 1, “Financial Statements” of this Quarterly Report on Form 10-Q

104*

Inline XBRL for the cover page of this Quarterly on Form 10-Q, included in the Exhibit 101 Inline XBRL Document Set

§ Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) and Item 601(b)(10).

# Indicates a management contract or compensatory plan.

* Filed herewith.

** Furnished herewith.

3329

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its

behalf by the undersigned thereunto duly authorized.


	MEDAVAIL HOLDINGS, INC.

Date: May ~~17, 2021~~13, 2022	By:	/s/ ~~Ed Kilroy~~Mark Doerr
		~~Ed Kilroy~~Mark Doerr
		President, ~~and~~ Chief Executive Officer, and Principal Executive Officer

	By:	/s/ Ramona Seabaugh
		Ramona Seabaugh
		Chief Financial Officer and Principal Financial Officer

3430


	Three Months Ended March 31, 2021
	Common Shares			Preferred Shares *			Warrants		Additional Paid-in-Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity (Deficit)
	Shares	Amount		Shares	Amount
Balance at December 31, 2020	31,816,020	$	32	—	$	—	$	2,614	$	213,624	$	(148,275)	$	(6,928)	$	61,067
Net loss	—	—		—	—		—		—		(9,452)		—		(9,452)
Shares issued for options exercises	120,924	—		—	—		—		201		—		—		201
Exercise of warrants	2,954	—		—	—		(35)		40		—		—		5
Share-based compensation	—	—		—	—		—		260		—		—		260

Balance at March 31, 2021	31,939,898	$	32	—	$	—	$	2,579	$	214,125	$	(157,727)	$	(6,928)	$	52,081







	Three Months Ended March 31, 2020
	Common Shares			Preferred Shares *			Warrants		Additional Paid-in-Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Deficit
	Shares	Amount		Shares	Amount
Balance at December 31, 2019	1,504,251	$	8	10,500,440	$	93,484	$	698	$	30,829	$	(121,230)	$	(6,950)	$	(3,161)
Net loss	—	—		—	—		—		—		(5,690)		—		(5,690)
Issuance of preferred shares	—	—		102,777	788		—		—		—		—		788
Shares issued for options exercises	17,160	—		—	—		—		27		—		—		27
Share-based compensation	—	—		—	—		—		84		—		—		84

Warrants issued	—	—		—	—		435		(11)		—		—		424
Cumulative translation adjustment	—	—		—	—		—		—		—		(2)		(2)
Balance at March 31, 2020	1,521,411	$	8	10,603,217	$	94,272	$	1,133	$	30,929	$	(126,920)	$	(6,952)	$	(7,530)